

MEDICIS PHARMACEUTICAL CORP

Form 11-K

June 30, 2004

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 11-K

**[X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the fiscal year ended: December 31, 2003

**TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 [NO FEE REQUIRED]**

For the transition period from _____ to _____

Commission file Number 001-14471

MEDICIS PHARMACEUTICAL CORPORATION 401(k) PLAN
(Full title of the Plan)

MEDICIS PHARMACEUTICAL CORPORATION

(Name of the issuer of the securities held pursuant to the Plan)

8125 NORTH HAYDEN ROAD
SCOTTSDALE, ARIZONA 85258

(Address of principal executive office of the issuer)

MEDICIS PHARMACEUTICAL CORPORATION 401(k) PLAN

Index of Financial Statements and Exhibits

Item

| | |
|--|--|
| Report of Independent Registered Public Accounting Firm | |
| Statements of Net Assets Available for Benefits at December 31, 2003 and 2002 | |
| Statement of Changes in Net Assets Available for Benefits for the Year Ended December 31, 2003 | |
| Notes to Financial Statements | |
| Schedule H, Line 4(i), Schedule of Assets (Held at End of Year) | |
| Schedule G, Part III, Schedule of Nonexempt Transactions for the Year Ended December 31, 2003 | |
| Signature | |
| Exhibit 23 Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm | |

Table of Contents

FINANCIAL STATEMENTS AND SUPPLEMENTAL SCHEDULES
Medicis Pharmaceutical Corporation 401(k) Plan
Year ended December 31, 2003

Medicis Pharmaceutical Corporation 401(k) Plan

Financial Statements and Supplemental Schedules

Year ended December 31, 2003

Contents

| | |
|--|----|
| <u>Report of Independent Registered Public Accounting Firm</u> | 1 |
| Financial Statements | |
| <u>Statements of Net Assets Available for Benefits</u> | 2 |
| <u>Statement of Changes in Net Assets Available for Benefits</u> | 3 |
| <u>Notes to Financial Statements</u> | 4 |
| <u>Supplemental Schedules</u> | |
| <u>Schedule of Assets (Held at End of Year)</u> | 9 |
| <u>Schedule of Delinquent Participant Contributions</u> | 10 |
| <u>Exhibit 23</u> | |

Table of Contents

Report of Independent Registered Public Accounting Firm

Medicis Pharmaceutical Corporation

As Plan Administrator of the Medicis Pharmaceutical Corporation 401(k) Plan

We have audited the accompanying statements of net assets available for benefits of Medicis Pharmaceutical Corporation 401(k) Plan as of December 31, 2003 and 2002, and the related statement of changes in net assets available for benefits for the year ended December 31, 2003. These financial statements are the responsibility of the Plan's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the net assets available for benefits of the Plan at December 31, 2003 and 2002, and the changes in its net assets available for benefits for the year ended December 31, 2003 in conformity with U.S. generally accepted accounting principles.

Our audits were performed for the purpose of forming an opinion on the financial statements taken as a whole. The accompanying supplemental schedules of assets (held at end of year) as of December 31, 2003, and delinquent participant contributions for the year then ended, are presented for the purposes of additional analysis and are not a required part of the financial statements but are supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. These supplemental schedules are the responsibility of the Plan's management. The supplemental schedules have been subjected to the auditing procedures applied in our audits of the financial statements and, in our opinion, are fairly stated in all material respects in relation to the financial statements taken as a whole.

Phoenix, Arizona

June 9, 2004

Table of Contents

Medicis Pharmaceutical Corporation 401(k) Plan

Statements of Net Assets Available for Benefits

| | December 31 | |
|---|--------------------|--------------------|
| | 2003 | 2002 |
| Assets | | |
| Cash | \$ 25,476 | \$ |
| Investments, at fair value | 9,261,312 | 5,429,290 |
| Employer contributions receivable | 84,456 | |
| Participant contributions receivable | 57,076 | 121,728 |
| Dividend receivable | 134 | |
| | <hr/> | <hr/> |
| Net assets available for benefits | \$9,428,454 | \$5,551,018 |
| | <hr/> | <hr/> |

See accompanying notes.

Table of Contents

Medicis Pharmaceutical Corporation 401(k) Plan

Statement of Changes in Net Assets Available for Benefits

Year Ended December 31, 2003

| | |
|---|---------------------------|
| Additions | |
| Interest and dividend income | \$ 153,659 |
| Employee contributions | 2,142,304 |
| Employer contributions | 457,858 |
| Net realized and unrealized appreciation in fair value of investments | <u>1,386,104</u> |
| | |
| Total additions | 4,139,925 |
| Deductions | |
| Benefits paid directly to participants | 261,919 |
| Administrative expenses | <u>570</u> |
| | |
| Total deductions | <u>262,489</u> |
| | |
| Net increase | 3,877,436 |
| Net assets available for benefits: | |
| Beginning of year | <u>5,551,018</u> |
| | |
| End of year | <u>\$9,428,454</u> |

See accompanying notes.

Table of Contents

\

Medicis Pharmaceutical Corporation 401(k) Plan

Notes to Financial Statements

December 31, 2003

1. Description of the Plan

General

The Medicis Pharmaceutical Corporation 401(k) Plan, as amended, (the Plan) is a defined contribution plan available to eligible employees of Medicis Pharmaceutical Corporation (the Company or Plan Sponsor). The Plan covers all nontemporary employees who have attained the age 21. There is no service requirement and employees may elect to join the Plan on their initial employment date. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (ERISA). For a more complete description of the Plan's provisions please refer to the Plan document.

Contributions

Effective 2002, participants may make pre-tax contributions up to 100 percent of their annual compensation as defined by the Plan, and subject to the annual limits of the Internal Revenue Code. Participants may also contribute amounts representing distributions from other qualified plans.

Effective April 2002, the Plan Sponsor changed its matching contributions from discretionary to an amount equal to 50 percent of the first 3 percent of the participant's contribution. In addition, the Plan Sponsor may, at its sole discretion, make a profit sharing contribution to the Plan for any Plan year. The amount of employer matching contributions during 2003 was \$457,858.

Participant Accounts

Each participant's account is credited with the participant's contributions and the allocation of Plan earnings. The benefit to which a participant is allowed is limited to the vested balance in his account.

Vesting

Participants vest immediately in their elective contributions plus actual earnings thereon, and such amounts are nonforfeitable. Vesting in the Company contribution portion of their accounts plus actual earnings thereon is based on years of continuous service. A participant is 20 percent vested after two full years of service and vests 60 percent after three years and 100 percent after four years. A participant becomes fully vested upon disability or death or reaching normal retirement age, as defined by the Plan.

Table of Contents

Medicis Pharmaceutical Corporation 401(k) Plan

Notes to Financial Statements (continued)

1. Description of the Plan (continued)

Participant Loans

Participants may borrow from their accounts a minimum of \$1,000 to a maximum equal to the lesser of \$50,000 or 50 percent of their vested account balance. Loan terms shall be no greater than five years except when used to purchase a primary residence.

Forfeitures

Forfeited balances of terminated participants' nonvested accounts are used to pay Plan expenses not paid by the Plan Sponsor and any forfeiture from Plan Sponsor matching or profit sharing contributions will be used to reduce future Plan Sponsor contributions. There were \$634 and \$502 of forfeited nonvested accounts in the Plan as of December 31, 2003 and 2002, respectively.

Benefit Payments

Upon termination of service for any reason, a participant's account is generally distributed in a single lump-sum payment upon request. At the Administrative Committee's option, if the account balance is \$5,000 or less, the entire balance may be distributed.

Plan Termination

Although it has not expressed any intent to do so, the Company has the right to terminate the Plan at any time, subject to the provisions of ERISA. In the event of a termination of the Plan, participants will become fully vested in their accounts.

Administrative Expenses

The Company typically pays the majority of the administrative fees for the Plan.

Table of Contents

Medicis Pharmaceutical Corporation 401(k) Plan

Notes to Financial Statements (continued)

2. Significant Accounting Policies

Basis of Accounting

The accompanying financial statements of the Plan have been prepared on an accrual basis.

Investments Valuation

All Plan investments are held by The Charles Schwab Trust Company (Charles Schwab or the Trustee). Investments in registered investment company mutual funds are valued at quoted market prices which represent the net asset value of shares held by the Plan at year-end. Investments in the collective investment trust are valued at fair market value as reported to the Plan by Charles Schwab. The shares of Medicis Pharmaceutical Corporation common stock are valued at quoted market prices at year-end. Participant loans are valued at their outstanding balance, which approximates fair value.

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date.

The realized gain or loss on investments is included with unrealized appreciation or depreciation in the current value of investments.

Investment securities are exposed to various risks, such as interest rate, credit and market volatility risks. The Plan's exposure to credit loss in the event of nonperformance of investments is limited to the carrying value of such investments. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in risks in the near term could materially affect the amounts reported in the Statements of Net Assets Available for Benefits.

Use of Estimates

The preparation of financial statements in conformity with U.S generally accepted accounting principles requires management to make estimates that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from these estimates.

Table of Contents

Medicis Pharmaceutical Corporation 401(k) Plan

Notes to Financial Statements (continued)

3. Investments

The fair value of individual investments that represent 5 percent or more of the Plan's net assets available for benefits is as follows as of December 31:

| | <u>2003</u> | <u>2002</u> |
|--|--------------------|-------------|
| Dreyfus Appreciation Fund | \$2,801,303 | * |
| Schwab Stable Value Fund | 915,315 | * |
| Schwab Managed Retirement 2030 | 766,985 | * |
| UBS U.S. Small Cap Growth | 714,406 | * |
| Medicis Pharmaceutical Corporation Class A Common Stock | 706,713 | * |
| William Blair International Growth Fund | 624,950 | * |
| Goldman Sachs Mid Cap Value A | 556,498 | * |
| Northern Select Equity Fund | 505,061 | * |
| Vanguard Index Trust 500 Portfolio | * | \$1,469,866 |
| Frank Russell Equity Q | * | 644,544 |
| INVESCO Retirement Stable Value | * | 630,605 |
| DFA US 9-10 Small Cap Portfolio | * | 477,686 |
| White Oak Growth Stock | * | 343,414 |
| Frank Russell Equity II Fund | * | 318,473 |
| Morgan Stanley Institutional International Equity Class A | * | 280,920 |

*Investment balance represents less than 5% of net assets for indicated year.

During 2003, the Plan's investments (including investments purchased, sold, as well as held during the year) appreciated in fair value as follows:

| | |
|-----------------------------|--------------------|
| Mutual funds | \$1,031,153 |
| Collective investment trust | 185,693 |
| Common stock | 169,258 |
| | <hr/> |
| Total | \$1,386,104 |
| | <hr/> |

Table of Contents

Medicis Pharmaceutical Corporation 401(k) Plan

Notes to Financial Statements (continued)

4. Income Tax Status

The Plan has received a determination letter from the Internal Revenue Service dated September 4, 2003, stating that the Plan is qualified under Section 401(a) of the Internal Revenue Code (IRC) and, therefore, the related trust is exempt from taxation. Once qualified, the Plan is required to operate in conformity with the IRC to maintain its qualification. The Plan Sponsor has indicated that it will take the necessary steps, if any, to maintain the Plan's qualified status.

5. Parties-In-Interest

Certain Plan investments are shares in mutual funds and collective investment trust funds managed by Charles Schwab. Because Charles Schwab is the Plan's trustee, these transactions qualify as party-in-interest transactions. In addition, certain Plan investments are in Medicis Pharmaceutical Corporation Class A Common Stock. These transactions also qualify as party-in-interest transactions. Still other Plan investments are made in the form of loans to Plan participants. These transactions also qualify as party-in-interest transactions.

6. Reconciliation to Form 5500

The following is a reconciliation of employee contributions for the year ended December 31, 2003, per the Form 5500, to the financial statements:

| | |
|---|--------------------|
| Employee contributions per the Form 5500 | \$2,264,032 |
| Contributions receivable at December 31, 2002 | (121,728) |
| | <hr/> |
| Employee contributions per the financial statements | \$2,142,304 |
| | <hr/> |

The following is a reconciliation of benefit payments as of December 31, 2003, per the Form 5500, to the financial statements:

| | |
|--|------------------|
| Benefit payments per the Form 5500 | \$190,284 |
| Change in benefits payable to withdrawing participants | 71,635 |
| | <hr/> |
| Benefit payments per the financial statements | \$261,919 |
| | <hr/> |

The following is a reconciliation of net assets available for benefits as of December 31, 2002 per the Form 5500, to the financial statements:

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 11-K

| | |
|--|--------------------|
| Net assets available for benefits per the Form 5500 | \$5,357,655 |
| Contributions receivable | 121,728 |
| Amounts allocated to withdrawing participants | <u>71,635</u> |
| Net assets available for benefits per the financial statements | <u>\$5,551,018</u> |

Table of Contents

Medicis Pharmaceutical Corporation 401(k) Plan

Notes to Financial Statements (continued)

7. Subsequent Event

On May 18, 2004, 68 plan participants were terminated as a result of the asset purchase agreement between Medicis Pharmaceutical Corporation and BioMarin Pharmaceutical, Inc. The accounts of these participants will be distributed in accordance with the Plan's benefit payments policy.

Table of Contents

Supplemental Schedules

Table of Contents

Medicis Pharmaceutical Corporation 401(k) Plan

Schedule H, Line 4(i)

Schedule of Assets (Held at End of Year)

EIN: 52-1574808 PN: 001

December 31, 2003

| Identity of Issue | Description of Asset | Cost | Current Value |
|---|-------------------------------|------|---------------|
| Mutual Funds: | | | |
| Cohen & Steers Realty Shares | Registered Investment Company | (a) | \$ 213,566 |
| Dreyfus Appreciation Fund | Registered Investment Company | (a) | 2,801,303 |
| Goldman Sachs Mid Cap Value A | Registered Investment Company | (a) | 556,498 |
| MFS Value Fund Class A | Registered Investment Company | (a) | 214,902 |
| Northern Select Equity Fund | Registered Investment Company | (a) | 505,061 |
| PIMCO Total Return Fund | Registered Investment Company | (a) | 64,479 |
| Templeton Foreign Fund | Registered Investment Company | (a) | 444,768 |
| UBS U.S. Small Cap Growth | Registered Investment Company | (a) | 714,406 |
| William Blair International Growth Fund | Registered Investment Company | (a) | 624,950 |
| Artisan Midcap Fund | Registered Investment Company | (a) | 15,933 |
| Brandywine Advisors Fund | Registered Investment Company | (a) | 4,017 |
| DFA Five-year Globalfixed Port | Registered Investment Company | (a) | 1,786 |
| DFA Five-year Government Portfolio | Registered Investment Company | (a) | 10,359 |
| DFA Real-estate Securities Portfolio | Registered Investment Company | (a) | 10,032 |
| DFA US Large Company Portfolio | Registered Investment Company | (a) | 12,208 |
| Janus Twenty Fund | Registered Investment Company | (a) | 3,506 |
| Janus Worldwide Fund | Registered Investment Company | (a) | 8,148 |
| Marsico Focus Fund | Registered Investment Company | (a) | 15,403 |
| NB Focus Fund | Registered Investment Company | (a) | 9,456 |
| Oakmark Fund | Registered Investment Company | (a) | 60,691 |
| PBHG Large Cap Growth Fund | Registered Investment Company | (a) | 3,818 |
| PBHG Technology & Communications Fund | Registered Investment Company | (a) | 5,700 |
| Pimco Low-duration Fund Instl Class | Registered Investment Company | (a) | 986 |
| Pimco Pea Innovation Fund Clid | Registered Investment Company | (a) | 6,639 |
| * Schwab S&P500 Inv Shs | Registered Investment Company | (a) | 5,083 |
| Tweedy Browne Global Value Fund | Registered Investment Company | (a) | 12 |
| Yacktman Focused Fund | Registered Investment Company | (a) | 4,174 |
| Collective Investment Trust: | | | |
| * Schwab Managed Retirement 2010 | Common Collective Trust Fund | (a) | 65,519 |
| * Schwab Managed Retirement 2020 | Common Collective Trust Fund | (a) | 275,911 |
| * Schwab Managed Retirement 2030 | Common Collective Trust Fund | (a) | 766,985 |
| * Schwab Stable Value Fund | Common Collective Trust Fund | (a) | 915,315 |
| Common Stock: | | | |

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 11-K

| | | | |
|--------------------------------------|---------------------------------|-----|-------------------|
| * Medicis Pharmaceutical Corporation | | | |
| Class A Common Stock | Employer Securities | (a) | 706,713 |
| * Participant loans | 5.0% to 10.5% interest; various | | |
| | maturities | (a) | 123,623 |
| Cash and Cash Equivalents: | | | |
| * Schwab Money Market Fund | Cash equivalents | (a) | 89,362 |
| | | | <u> </u> |
| | | | \$9,261,312 |
| | | | <u> </u> |

* Party in interest.

(a) Disclosure of historical cost information is not required for participant-directed investments.

Table of Contents

Medicis Pharmaceutical Corporation 401(k) Plan

Schedule H, Line 4a

Schedule of Delinquent Participant Contributions

EIN: 52-1574808 PN: 001

For the year ended December 31, 2003

| Participant Contributions Transferred Late to Plan | Total that Constitute Nonexempt Prohibited Transactions |
|---|--|
| <hr/> <p>\$864,062</p> | <hr/> <p>\$864,062</p> |

Table of Contents

SIGNATURE

The Plan. Pursuant to the requirements of the Securities and Exchange Act of 1934 the Plan Administrator has duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

**MEDICIS PHARMACEUTICAL
CORPORATION 401(k) PLAN**

(Full Title of the Plan)

Date: June 30, 2004

By: /s/ MARK A. PRYGOCKI, SR.

Mark A. Prygocki, Sr.

Executive Vice President, Chief Financial
Officer, Corporate Secretary and
Treasurer of Medicis Pharmaceutical
Corporation, issuer of the securities held
pursuant to the Plan (Plan Administrator)